Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5206
ISSN (Online): 1875-5992

Research Article

4-Anilinoquinazoline Derivatives with Epidermal Growth Factor Receptor Inhibitor Activity

Author(s): Fang Liu, Baoding Tang, Hao Liu, Leina Li, Gang Liu, Yun Cheng, Yan Xu, Wenwen Chen and Yinjiu Huang

Volume 16, Issue 12, 2016

Page: [1652 - 1664] Pages: 13

DOI: 10.2174/1871520616666160404113141

Price: $65

Abstract

4-Anilinoquinazoline derivatives possess high anti-cancer activities. Many of them are highly selective tyrosine kinase inhibitors (TKI), particularly against epidermal growth factor receptor (EGFR). EGFRs are overexpressed or mutated in most carcinomas and are required for tumor progression. The efficacy of EGFR-targeted anti-tumor drugs is impaired by drug-induced acquired resistance. Therefore, there is urgency to find better anti-cancer agents with novel effects on EGFR. 4-Anilinoquinazolines are small molecule EGFR inhibitors that have been synthesized and assessed for their anti-tumor bioactivity. In this paper, we review the 4-anilinoquinazoline derivatives with EGFR inhibitor activity reported in recent years.

Keywords: 4-anilinoquinazoline, Anti-tumor activity, Epidermal growth factor receptor (EGFR).

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy